Shopping Cart
Remove All
Your shopping cart is currently empty
Mapatumumab (Synonyms: HGS-ETR1, HGSETR1, HGS-1012, HGS1012, Anti-Human TNFRSF10A Recombinant Antibody)
Catalog No. T77371 Copy Product Info
🥰Excellent
Mapatumumab (HGS-ETR1) is a fully human agonistic monoclonal antibody targeting TNF-related apoptosis-inducing ligand receptor 1, with anticancer activity, capable of inducing apoptosis in cancer cells.
Mapatumumab
Copy Product Info🥰Excellent
Catalog No. T77371
Synonyms HGS-ETR1, HGSETR1, HGS-1012, HGS1012, Anti-Human TNFRSF10A Recombinant Antibody
Mapatumumab (HGS-ETR1) is a fully human agonistic monoclonal antibody targeting TNF-related apoptosis-inducing ligand receptor 1, with anticancer activity, capable of inducing apoptosis in cancer cells.
Mapatumumab
Cas No. 658052-09-6
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $249 | - | In Stock | |
| 5 mg | $747 | - | In Stock | |
| 10 mg | $1,190 | - | In Stock | |
| 25 mg | $1,990 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.85% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Mapatumumab (HGS-ETR1) is a fully human agonistic monoclonal antibody targeting TNF-related apoptosis-inducing ligand receptor 1, with anticancer activity, capable of inducing apoptosis in cancer cells. |
| Targets&IC50 | TNFRSF10A/TRAILR1 (human):17.21 ng/mL (EC50) |
| In vitro | Mapatumumab (0.01-100 μg/mL) showed very limited activity against 23 cell lines of PPTP cultured in vitro, with no cell lines achieving 50% growth inhibition. [1] Mapatumumab (1-100 ng/ml) and EPI (0.1-10 μg/ml) treated bladder cancer cells for 24 h, and showed significantly enhanced cytotoxicity and synergistic effect. Mapatumumab (100 ng/ml) does not activate T24 cells casapse-8, casapse-9 and casapse-3. [2] |
| In vivo | Mapatumumab (10 mg/kg intrperitoneally administered twice weekly for six weeks), two neuroblastoma xenotransplantation models (NB-1643 and NB-SD) showed excessive toxicity. [1] |
| Synonyms | HGS-ETR1, HGSETR1, HGS-1012, HGS1012, Anti-Human TNFRSF10A Recombinant Antibody |
| Reactivity | Human |
| Verified Activity | Immobilized Human TNFRSF10A/TRAILR1/CD261 Protein (His) at 2 μg/mL can bind Mapatumumab. The EC50 is 0.01721 μg/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF10A/TRAILR1/CD261 |
| Molecular Weight | 143.52 kDa |
| Cas No. | 658052-09-6 |
| Isotype | Human IgG2SA lambda2 |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Mapatumumab | purchase Mapatumumab | Mapatumumab cost | order Mapatumumab | Mapatumumab in vivo | Mapatumumab in vitro | Mapatumumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.